Sera (Donor An­i­mals)

Sera from donor animals are used to protect acutely sick patients from dangerous diseases (e.g. botulism toxin) or to prevent the body from rejecting an organ transplant. The appropriate serum is produced by immunising the donor animals against the specific antigen first, to ensure that there is an appropriate amount of antibody in the blood. 

Name De­scrip­tion Mar­ket­ing Au­tho­ri­sa­tion Hold­er Li­cense Num­ber Li­cense Date Use Further Information


An­ti-Hu­man-T-Lym­phozyten-Im­mun­glob­u­lin vom Pferd (eATG)

Pfiz­er GmbH

PEI.H.12030.01.1 28.01.2022 Pferd


An­ti-Hu­man-T-Zell-Lym­phozyten­glob­u­lin vom Kan­inchen

Neovii Biotech GmbH

452a/87 08.02.1988 Kaninchen


Polyk­lonales An­ti-Lym­phozyten-Serum

Gen­zyme Eu­rope B.V.

191a/92 04.08.1994 Kaninchen



The list of medicines contains the products that have a valid marketing authorization. It contains no information as to whether the preparations are available on the market.

The information contained in the Federal Gazette, which is the official publication organ of the Paul-Ehrlich-Institut, is legally binding.

As of: PEI announcement No. 495 in BAnz AT 12.07.2022 B2.

Summary of Product Characteristics (SmPCs) and the Package Leaflet (PL)

Where the European Medicines Agency (EMA) offers further information, you will find a link to the EPAR (European public assessment report) in the table.

If user and technical information or public assessment reports are available in PharmNet.Bund, the Federal and State Pharmaceutical Information Portal, these are directly linked to PharmNet.Bund in the table.

Updated: 12.07.2022